

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6383160

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
OXFORD FINANCE LLC, AS COLLATERAL AGENT	10/30/2020

RECEIVING PARTY DATA

Name:	BELLICUM PHARMACEUTICALS, INC.
Street Address:	2130 WEST HOLCOMBE BOULEVARD, SUITE 800
City:	HOUSTON
State/Country:	TEXAS
Postal Code:	77030

PROPERTY NUMBERS Total: 15

Property Type	Number
Patent Number:	10525110
Patent Number:	9434935
Patent Number:	9913882
Patent Number:	9932572
Patent Number:	9944690
Application Number:	14622018
Application Number:	16788062
Application Number:	14842710
Application Number:	14968737
Application Number:	14968853
Application Number:	15377776
Application Number:	15901556
Application Number:	15910380
Application Number:	16734104
Application Number:	16611772

CORRESPONDENCE DATA

Fax Number: (415)693-2222

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4156932000

Email: crhem@cooley.com
Correspondent Name: COOLEY LLP
Address Line 1: 101 CALIFORNIA STREET, 5TH FLOOR
Address Line 4: SAN FRANCISCO, CALIFORNIA 94111

ATTORNEY DOCKET NUMBER: 306803-100

NAME OF SUBMITTER: C. RHEM

SIGNATURE: /CR/

DATE SIGNED: 11/03/2020

Total Attachments: 3

source=Bellicum - Oxford IP Release (10-2020)#page1.tif

source=Bellicum - Oxford IP Release (10-2020)#page2.tif

source=Bellicum - Oxford IP Release (10-2020)#page3.tif

REASSIGNMENT AND RELEASE OF SECURITY INTEREST

This Reassignment and Release of Security Interest is executed as of October 30, 2020 by OXFORD FINANCE LLC, a Delaware limited liability company as Collateral Agent (the "Assignor") for the benefit of BELLICUM PHARMACEUTICALS, INC., a Delaware corporation ("Assignee"), having its principal business address located at 2130 West Holcombe Boulevard, Suite 800, Houston, TX 77030.

RECITALS

A. WHEREAS, Assignee granted and pledged certain security interests in the intellectual property described on Exhibit A and Exhibit B (together, the "Intellectual Property Collateral") to the Assignor pursuant to a certain Intellectual Property Security Agreement dated as of March 31, 2020 and recorded on April 1, 2020 with the U.S. Patent and Trademark Office (i) Patent Division at Reel/Frame 052284/0113 and (ii) Trademark Division Reel/Frame 6904/0898; and

B. WHEREAS, Assignor wishes to release and reassign all interest that Assignor may have in the Intellectual Property Collateral.

AGREEMENT

Now, therefore, Assignor agrees that it releases its security interests in the Intellectual Property Collateral and reassigns to Assignee, without warranty or recourse, all interest of Assignor in the Intellectual Property Collateral.

ASSIGNOR:

Address:

133 North Fairfax Street
Alexandria, VA 22314

OXFORD FINANCE LLC, AS COLLATERAL
AGENT


By: 
Name: Joshua Friedman
Title: Chief Financial Officer

EXHIBIT A

Patents

<u>Description</u>	<u>Patent/App. No.</u>	<u>Issue/File Date</u>
Methods for inducing partial apoptosis using caspase polypeptides	10525110	1/7/20
Modified caspase polypeptides and uses thereof	9434935	9/6/16
Methods for inducing partial apoptosis using caspase polypeptides	9913882	3/13/18
Modified caspase polypeptides and uses thereof	9932572	4/3/18
Methods for controlling T cell proliferation	9944690	4/17/18
Methods for activating T cells using an inducible chimeric polypeptide	14622018	2/13/15
Costimulation of chimeric antigen receptors by MYD88 and CD40 polypeptides	16788062	2/11/20
Costimulation of chimeric antigen receptors by MYD88 and CD40 polypeptides	14842710	9/1/15
Methods for controlled elimination of therapeutic cells	14968737	12/14/15
Methods for controlled activation or elimination of therapeutic cells	14968853	12/14/15
Dual controls for therapeutic cell activation or elimination	15377776	12/13/16
Modified caspase polypeptides and uses thereof	15901556	2/21/18
Methods for controlling T cell proliferation	15910380	3/2/18
Methods for inducing partial apoptosis using caspase polypeptides	16734104	1/3/20
Methods to augment or alter signal transduction	16611772	5/8/18

EXHIBIT B

Trademarks

<u>Description</u>	<u>Serial No.</u>	<u>File Date</u>
GOCAR-T	86218763	3/12/14
CASPACIDE	85148750	10/8/10
BELLICUM	85014486	4/15/10